CJC-1295 No DAC (Mod GRF 1-29)

5.8

Worth trying, BioHarmony verdict

BioHarmony score 5.8 out of 10

CJC-1295 No DAC (Mod GRF 1-29) is a short-acting GHRH peptide, almost always stacked with ipamorelin, that prompts a pulse of your own growth hormone. Human data exists only for the long-acting DAC version, per Teichman 2006; the no-DAC form has no dedicated human trial, and neither form has a human outcome study.

Read full report

What is CJC-1295 No DAC (Mod GRF 1-29)?

CJC-1295 No DAC, better known as Mod GRF 1-29, is a lab-made peptide that nudges your own pituitary to release a short pulse of growth hormone, and the "No DAC" part is the whole point. It activates the growth-hormone-releasing-hormone receptor, then clears in about 30 minutes, so it mimics the brief, natural rise and fall your body produces on its own. That is the version people stack with ipamorelin. Its long-acting sibling, CJC-1295 with DAC, binds to albumin and keeps growth hormone elevated for 6 to 8 days, a sustained "bleed" most experienced users avoid as non-physiological.

From the BioHarmony report, reviewed Sep 19, 2026.

Saved on this device only.

Safety watch-outs

  • Worsening or progressive reaction with each injection (possible sensitization): stop immediately.
  • New or worsening numbness or tingling (possible fluid-related nerve compression): reduce dose or stop.
  • Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes.
  • Any active or suspected cancer: do not use
  • growth-hormone-axis stimulation is contraindicated.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for CJC-1295 No DAC (Mod GRF 1-29) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established

FDA identifies immunogenicity and peptide-impurity concerns for compounded CJC-1295 and reports limited clinical data plus serious adverse events.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.